Gilead Sciences, Inc. revenue by year
Over the 10 fiscal years shown, revenue went from $30.39B (year ended Dec 31, 2016) to $29.44B (year ended Dec 31, 2025), a compound annual growth rate of -0.4%. The fastest growth was +10.6% in the year ended Dec 31, 2021; the weakest year was −15.2% (year ended Dec 31, 2018).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $29.44B | +2.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 24, 2026 |
| Dec 31, 2024 | $28.75B | +6.0% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 24, 2026 |
| Dec 31, 2023 | $27.12B | −0.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 24, 2026 |
| Dec 31, 2022 | $27.28B | −0.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 28, 2025 |
| Dec 31, 2021 | $27.30B | +10.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 23, 2024 |
| Dec 31, 2020 | $24.69B | +10.0% | Revenues | 10-K filed Feb 25, 2021 |
| Dec 31, 2019 | $22.45B | +1.5% | Revenues | 10-K filed Feb 25, 2021 |
| Dec 31, 2018 | $22.13B | −15.2% | Revenues | 10-K filed Feb 25, 2021 |
| Dec 31, 2017 | $26.11B | −14.1% | Revenues | 10-K filed Feb 25, 2020 |
| Dec 31, 2016 | $30.39B | −6.9% | Revenues | 10-K filed Feb 26, 2019 |
Gilead Sciences, Inc. reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 30, 2026 | $8.30B | +6.8% | 10-Q filed Oct 30, 2026 |
| 3 months ended Jun 30, 2026 | $7.80B | +10.2% | 10-Q filed Aug 6, 2026 |
| 3 months ended Mar 31, 2026 | $6.96B | +4.4% | 10-Q filed May 7, 2026 |
| 3 months ended Sep 30, 2025 | $7.77B | +3.0% | 10-Q filed Oct 30, 2026 |
| 3 months ended Jun 30, 2025 | $7.08B | +1.8% | 10-Q filed Aug 6, 2026 |
| 3 months ended Mar 31, 2025 | $6.67B | −0.3% | 10-Q filed May 7, 2026 |
| 3 months ended Sep 30, 2024 | $7.54B | +7.0% | 10-Q filed Nov 7, 2025 |
| 3 months ended Jun 30, 2024 | $6.95B | +5.4% | 10-Q filed Aug 7, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 882095 (raw data). Most recent filing in this dataset: 10-Q filed Oct 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.